SCHEMBL4630007

SCHEMBL4630007

COc1ccc(S(=O)(=O)c2cc3cc(Br)ccc3[nH]2)cc1NC1CCN(C)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.49
CYP2D6 P10635 5/20 0.49
HTR7 P34969 4/20 0.46
DRD2 P14416 3/20 0.46
HTR2A P28223 3/20 0.46
HTR2C P28335 3/20 0.46
ADRA1B P35368 3/20 0.46
SLC6A2 P23975 2/20 0.46
HRH1 P35367 2/20 0.46
SLC6A3 Q01959 2/20 0.46
KCNH2 Q12809 2/20 0.46
SLC6A4 P31645 1/20 0.46
HTR6 P50406 7/20 0.41
HTR4 Q13639 2/20 0.39
CYP1A2 P05177 1/20 0.39
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR1E P28566 1/20 0.39
HTR1F P30939 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629546 0.91 CYP3A4 (0.50) CYP3A4CYP2D6HTR7DRD2HTR2A
SCHEMBL4630164 0.89 CYP3A4 (0.56) CYP3A4CYP2D6HTR7DRD2HTR2A
SCHEMBL4628929 0.89 KCNH2 (0.56) CYP3A4CYP2D6HTR7DRD2HTR2A
SCHEMBL4628912 0.88 CYP3A4 (0.41) CYP3A4CYP2D6HTR7DRD2HTR2A
SCHEMBL2223601 0.83 CYP3A4 (0.55) CYP3A4CYP2D6HTR7DRD2HTR2A
Hydrochloric Acid SCHEMBL2224607 0.82 CYP3A4 (0.54) CYP3A4CYP2D6HTR7DRD2HTR2A
SCHEMBL4629547 0.81 CA2 (0.45) CYP3A4CYP2D6HTR7DRD2HTR2A
SCHEMBL4630178 0.81 HTR6 (0.44) CYP3A4CYP2D6HTR7DRD2HTR2A
SCHEMBL4629379 0.79 CYP3A4 (0.54) CYP3A4CYP2D6HTR7DRD2HTR2A
SCHEMBL16986597 0.79 CYP3A4 (0.57) CYP3A4CYP2D6HTR7DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017200792-A1 RUTHENIUM-SPHINGOMYELIN COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF TUMORS GARNETT MCKEEN LAB, INC. (US) 2017-11-23 WO disclosed
EP-2870256-A1 INACTIVATION OF A PRODUCTION STRAIN USING A FATTY ACID Novozymes A/S (DK) 2015-05-13 EP disclosed
EP-2814327-A1 FOOD COMPOSITION COMPRISING VITAMIN K AND SATURATED FAT AND ITS USE FrieslandBrands B.V. (NL) 2014-12-24 EP disclosed
WO-2014006040-A1 INACTIVATION OF A PRODUCTION STRAIN USING A FATTY ACID NOVOZYMES A/S (DK) 2014-01-09 WO disclosed
WO-2013122465-A1 FOOD COMPOSITION COMPRISING VITAMIN K AND SATURATED FAT AND ITS USE FRIESLAND BRANDS B.V. (NL) 2013-08-22 WO disclosed
EP-1919896-A1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. Suven Life Sciences Limited (IN) 2008-05-14 EP disclosed
EP-1917007-A2 INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS Rheoscience A/S (DK) 2008-05-07 EP disclosed
WO-2007020652-A1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. SUVEN LIFE SCIENCES LIMITED (IN) 2007-02-22 WO disclosed
WO-2007006319-A2 INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS RHEOSCIENCE A/S (DK) 2007-01-18 WO disclosed